We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+27.41%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.58B
AUM Growth
-$40.8M
Cap. Flow
-$216M
Cap. Flow %
-8.36%
Top 10 Hldgs %
47.96%
Holding
78
New
7
Increased
10
Reduced
27
Closed
8

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$33.1M
2
VTYX
Ventyx Biosciences
VTYX
+$30.2M
3
PEN icon
Penumbra
PEN
+$28.7M
4
PLRX icon
Pliant Therapeutics
PLRX
+$27.5M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$26.3M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$151M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$72.8M
3
ARGX icon
argenx
ARGX
+$39.2M
4
SKIN icon
SkinHealth Systems
SKIN
+$38.9M
5
CNC icon
Centene
CNC
+$33M

Sector Composition

Rank Sector Weight
1 Healthcare 98.01%
2 Consumer Staples 0.96%
3 Industrials 0.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELV icon
26
Elevance Health
ELV
$81.9B
$32M 1.24%
70,487
-13,500
-16% -$6.46M
SNCE
27
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$31.9M 1.24%
990,412
– –
PRTA icon
28
Prothena Corp
PRTA
$458M
$31.9M 1.24%
525,575
-210,600
-29% -$6.66M
SYK icon
29
Stryker
SYK
$127B
$31.9M 1.24%
+157,321
New +$33.1M
TRDA icon
30
Entrada Therapeutics
TRDA
$227M
$30.8M 1.19%
1,954,419
– –
MDVL
31
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$26.9M 1.04%
692,090
+188,235
+37% +$10.8M
OSH
32
DELISTED
Oak Street Health, Inc.
OSH
$26M 1.01%
1,061,295
-322,324
-23% -$8.53M
ABSI icon
33
Absci
ABSI
$1.28B
$25.1M 0.98%
8,031,094
– –
SKIN icon
34
SkinHealth Systems
SKIN
$94.9M
$24.9M 0.96%
2,109,564
-3,076,784
-59% -$38.9M
ATRA icon
35
Atara Biotherapeutics
ATRA
$71.2M
$23.6M 0.92%
249,710
– –
CNC icon
36
Centene
CNC
$31.3B
$22M 0.85%
282,460
-368,987
-57% -$33M
SRRK icon
37
Scholar Rock
SRRK
$5.71B
$21.8M 0.84%
3,140,026
-263,900
-8% -$2.2M
ANNX icon
38
Annexon
ANNX
$855M
$21.6M 0.84%
3,503,190
– –
AUGX
39
DELISTED
Augmedix, Inc. Common Stock
AUGX
$20.9M 0.81%
14,380,327
– –
RAPT
40
DELISTED
RAPT Therapeutics
RAPT
$18.9M 0.73%
98,104
-4,125
-4% -$780K
IONS icon
41
Ionis Pharmaceuticals
IONS
$9.35B
$18M 0.7%
+407,659
New +$17.2M
GRTS
42
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$17.9M 0.69%
6,952,760
– –
STVN icon
43
Stevanato
STVN
$5.37B
$16M 0.62%
946,825
-169,000
-15% -$2.84M
ALLK
44
DELISTED
Allakos
ALLK
$15.6M 0.6%
2,545,275
– –
STTK icon
45
Shattuck Labs
STTK
$710M
$15.2M 0.59%
5,619,914
– –
KLRS
46
Kalaris Therapeutics
KLRS
$88.7M
$15.1M 0.58%
82,955
+47,156
+132% +$7.35M
LVTX
47
DELISTED
LAVA Therapeutics
LVTX
$12.9M 0.5%
2,816,196
– –
RVMD icon
48
Revolution Medicines
RVMD
$40.2B
$12.3M 0.48%
+625,000
New +$13.7M
JAZZ icon
49
Jazz Pharmaceuticals
JAZZ
$15.9B
$10.9M 0.42%
81,464
-11,800
-13% -$1.79M
STOK icon
50
Stoke Therapeutics
STOK
$1.82B
$10.7M 0.42%
835,830
-1,157,438
-58% -$18.4M
1
2
3 4

Similar funds

KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Redmile Group's Q3 2022 Portfolio in Review

As of Q3 2022, Redmile Group held 78 positions worth $2.58B, down 1.6% from $2.62B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group withdrew a net $216M in Q3 2022, closing 8 positions and reducing 27 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $151M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Redmile Group opened a new position in Stryker worth $31.9M.

  • Redmile Group's largest Q3 2022 buy was Stryker: 157,321 shares worth $31.9M.
  • Redmile Group added most to Pliant Therapeutics in Q3 2022, an estimated $27.5M increase.
  • Redmile Group's biggest Q3 2022 reduction was argenx, cutting an estimated $39.2M.
  • Redmile Group fully exited Seagen Inc. Common Stock in Q3 2022, selling an estimated $151M.
  • Redmile Group's ten largest holdings make up 48% of its $2.58B portfolio in Q3 2022.
  • Redmile Group opened 7 new positions and closed 8 in Q3 2022.
  • Redmile Group's portfolio value fell 1.6% quarter-over-quarter to $2.58B.

Based on Redmile Group's 13F filing for Q3 2022, filed 14 Nov 2022.